MA 12.05 Genomic Profiling of EGFR T790M Mutated Non-Small Cell Lung Cancer to Evaluate the Mechanisms of Resistance to Osimertinib

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i> -Mutant NSCLC

Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1542 · Cited by 387 · see citing works

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors

Schrock, A. B., Zhu, V. W., Hsieh, W.-S., Madison, R. W., Creelan, B., Silberberg, J., Costin, D., Bharne, A., Bonta, I. R., Bosemani, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.027 · Cited by 146 · see citing works

Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer

Zhu, V. W., Klempner, S. J., & Ou, S. I. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.09.008 · Cited by 73 · see citing works

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y. W., Liu, H., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03593-3 · Cited by 23 · see citing works

Additional file 3 of RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y., Liu, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20933524

Additional file 6 of RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y., Liu, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20933533

Additional file 5 of RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y., Liu, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20933530

Additional file 2 of RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y., Liu, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20933521

Additional file 4 of RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y., Liu, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20933527

Additional file 1 of RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

Wang, C., Zhang, Z., Sun, Y., Wang, S., Wu, M., Ou, Q., Xu, Y., Chen, Z., Shao, Y., Liu, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20933518

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

Minari, R., Bordi, P., Del Re, M., Facchinetti, F., Mazzoni, F., Barbieri, F., Camerini, A., Comin, C. E., Gnetti, L., Azzoni, C., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.011 · Cited by 105 · see citing works

Impact of next-generation sequencing on clinical outcomes in advanced EGFR-mutant lung cancer patients after resistance to osimertinib.

Cheng, J.-T., Yang, J., & Wu, Y.-L. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.e20726 · Cited by 2 · see citing works

19P Predictors of osimertinib response at second-line treatment in EGFR mutant non-small cell lung cancer patients with acquired T790M resistance mutation

Doğan, İ., Gürbüz, M., Paksoy, N., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.2015

Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report

Zhang, Y., He, B., Zhou, D., Li, M., & Hu, C. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s188612 · Cited by 38 · see citing works

57P Acquired concurrent EGFR T790M and driver gene resistance from EGFR-TKIs hampered osimertinib efficacy in advanced lung adenocarcinoma

Wu, F., Zeng, Y., Feng, Y., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.066 · Cited by 1 · see citing works